Backed by $15m in NIDA Funding, NYU and B.More Team Up to Trial Psilocybin for Opioid Use Disorder

Words by Josh Hardman, edited by Michael Haichin. Psychedelic researcher Michael Bogenschutz has scored a $15 million grant from the National Institute on Drug Abuse (NIDA) to support a phase 2 clinical trial of psilocybin in the treatment of opioid use disorder (OUD). The agency will provide $3 million per year for a total of five years, with latter disbursements dependent on the outcome of a…

Source